Document:

Unassociated Document

    EXHIBIT
4.4

     

     

    THIS
WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN
REGISTERED UNDER THE ISRAELI SECURITIES LAW, 5728-1968, AS AMENDED, THE U.S.
SECURITIES ACT OF 1933, AS AMENDED OR UNDER ANY APPLICABLE U.S. STATE SECURITIES
LAWS (COLLECTIVELY, THE “SECURITIES
LAWS”). THEY
MAY NOT BE OFFERED FOR SALE, SOLD, CONVEYED, TRANSFERRED, PLEDGED, GIFTED,
ASSIGNED, ENCUMBERED OR OTHERWISE DISPOSED OF UNLESS (1) REGISTERED UNDER SUCH
SECURITIES LAWS, OR (2) PURSUANT TO AVAILABLE EXEMPTIONS FROM REGISTRATION FROM
SUCH SECURITIES LAWS AND THE RULES PROMULGATED THEREUNDER, PROVIDED THAT THE
HOLDER DELIVERS TO THE COMPANY AN OPINION OF COUNSEL, SATISFACTORY TO THE
COMPANY, CONFIRMING THE AVAILABILITY OF SUCH EXEMPTION. INVESTORS SHOULD BE
AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT
FOR AN INDEFINITE PERIOD OF TIME.

     

     

    BIOCANCELL
THERAPEUTICS INC. ASSIGNABLE
WARRANT

     

    To
purchase

    Shares
of Common Stock (subject to adjustment) of 

    BIOCANCELL THERAPEUTICS INC. (the “Company”)

    at
a per share price and subject to the terms detailed below 

    VOID
AFTER 17:00 p.m. Eastern Standard Time 

    on
the last day of the Warrant Period (as defined below)

     

     

     

    THIS IS TO CERTIFY
THAT, [_________________] (the “Holder”) is entitled to
purchase from the Company up to [__________] fully paid and non-assessable
shares of Common Stock of the Company, nominal value US$.0l per share (the “Common Stock”) comprising (i)
the Purchased Shares (as such term is defined in the Subscription Agreement to
which this Warrant is attached (the “Subscription Agreement”)) and (ii) the
number of shares of Common Stock underlying the Convertible Debenture (as such
term is defined in the Subscription Agreement), subject to adjustment as set
forth herein (the “Warrant Shares”), at an exercise
price per Warrant Share equal to US$ [_____] as may be adjusted hereunder
(which, for convenience and indication purposes only, was equal to
NIS [___] on the relevant date) (the “Exercise Price”), during the
period commencing upon the date hereof and terminating upon the lapse of five
(5)
years following the Closing Date (as such term is defined in the
Subscription Agreement) (the “Warrant Period”). Notwithstanding
the foregoing, in the event that the Average Price (as defined in the
Subscription and Registration Rights Agreement) is lower than US$ 0.743 or
higher than US$ 0.821 (i.e., five percent lower or higher than the PPS (as
defined in the Subscription and Registration Rights Agreement)), the Exercise
Price shall be adjusted to the lower of: (i) the Average Price (in US$)
multiplied by 1.20, and (ii) the closing price of the shares of Common Stock of
the Company, as reported on the Tel Aviv Stock Exchange, on the Determination
Date (as defined in the Subscription and Registration Rights Agreement)
multiplied by 1.25. The Average Price and the closing price in subsection (ii)
shall be denominated in US$ by dividing the Average Price or the closing price
denominated in NIS by the exchange rate of the US$ to NIS at the close of
business of the Determination Date.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    Notwithstanding,
in the event that the Loan Amount is converted prior to the end of the first
quarter following the second anniversary of the Closing, in accordance with the
terms of the Convertible Debenture, then the number of Warrant Shares shall be
decreased accordingly, to equal the portion of the interest attributable to the
Loan Amount that was so converted divided by the Exercise Price as adjusted. For
example, if the Convertible Debenture is converted on the Closing Date, the
number of Warrant Shares shall be decreased by 540,480.

     

    
      
        	
                1. 
      

              	
                EXERCISE
      OF WARRANT

              

      

    

     

    1.1. 
Cash Exercise of Warrant. This
Warrant may be exercised from time to time or at any time
during the Warrant Period by presentation and surrender thereof to the Company
at its principal office or at such other office or agency as it may designate
from time to time, accompanied by:

     

    1.1.1.
A duly executed notice of exercise, in the form attached hereto as Exhibit A (the “Exercise Notice”);
and

     

    1.1.2.
Payment to the Company, for the account of the Company, of the aggregate
Exercise Price for the number of Warrant Shares specified in the applicable
Exercise Notice, payable in immediately available funds by wire transfer to the
Company’s
bank account or by banker’s check or by any
other means of payment agreed upon between the Company and the Holder. The
Exercise Price will be paid in U.S. Dollars.

     

    1.2.
Exercise on a Net-Issuance Basis.

     

    In
lieu of payment to the Company of the Exercise Price as set forth in Section 1.1
above, the Holder may exercise the Warrant in whole or in part, into the number
of shares of Common Stock of the Company calculated pursuant to the following
formula, by surrendering the Warrant to the Company at the principal office of
the Company, accompanied by a written notice of exercise, specifying the portion
of the Warrant which the Holder desires to exercise:

     

    
      

      
        
          
            
              
                
                  
                    	
                            X =
      Y*
      (A-B)

                          
	          
      A

                  

                

              

            

          

        

      

    

     

    
      	
              Where:

            

    

     

    X
= the
number of
shares of Common Stock to be issued to the Holder;

     

    Y
= the
number of
shares of Common Stock obtainable upon exercise of the relevant portion of
the Warrant;

     

    A
=
the average closing price of a share of Common Stock of the Company in
the principal securities exchange on which the Company's shares are traded at
such time over a sixty (60) trading day period preceding the exercise date;
and

     

    B
=
the Exercise Price of a Warrant Share, as adjusted.

     

    
      
        
        

      

      
        - 2
-

        
          

        

      

      
        
        

      

    

     

    Execution
Copy

     

     

    1.3.
Partial Exercise,
Etc.   If this Warrant should be exercised in part only, the
Company shall,
upon surrender of this Warrant for cancellation, execute and deliver a new
Warrant evidencing
the rights of the Holder to purchase the balance of the Warrant Shares
purchasable
hereunder.

     

    1.4.
Issuance of Warrant Shares. Upon
presentation and surrender of this Warrant accompanied
by a duly executed Exercise Notice and (unless the Holder elects to exercise
the Warrant on a net-issuance basis) the payment of the applicable aggregate
Exercise
Price pursuant to Section 1.1 above, the Company shall promptly (i) issue to
the
Holder the Warrant Shares to which the Holder is entitled; and (ii) deliver to
the Holder
the share certificate(s) evidencing such Warrant Shares together with cash, as
provided
in Section 1.5 hereof, in respect of any fractional Warrant Shares otherwise
issuable
upon such surrender. Upon receipt by the Company of this Warrant, the
applicable
Exercise Notice and (unless the Holder elects to exercise the Warrant on a
net-issuance
basis) the applicable aggregate Exercise Price, the Holder shall be deemed
to
be the holder of record of the Warrant Shares issuable upon such exercise,
notwithstanding
that the stock transfer books of the Company shall then be closed or that
certificates
representing such stock shall not then be actually delivered to the
Holder.

     

    1.5. Fractional Shares. No fractions of
shares shall be issued in connection with the exercise of
this Warrant, and the number of shares issued shall be rounded up to the nearest
whole number (with cash being paid by the Company for any unissued fractional
shares).

     

    1.6.
Taxes. The Holder acknowledges
that the grant of the Warrant, the issue of the Warrant Shares
and the execution and/or performance of this Warrant may have tax consequences
to the Holder and that the Company is not able to ensure or represent to
the
Holder the nature and extent of such tax consequences. The Company shall pay all
of the
applicable taxes and other charges in connection with the issuance of the
Warrant Shares
and the preparation and delivery of share certificates pursuant to this Section
1 in the
name of the Holder (such as documentary stamp or similar issue or transfer taxes
in respect
of the issue or delivery of Common Shares on exercise of this Warrant), but
shall not
pay any taxes payable by the Holder by virtue of the sale of this Warrant or the
Warrant
Shares by the Holder and the Holder shall indemnify the Company, without
derogating
from the Holder's obligation to pay such amounts, for any and all charges or
payments
as aforesaid. The Company shall withhold required taxes pursuant to applicable
law on payments to the Holder under this Warrant, unless the Holder shall
provide
the Company with written confirmation of withholding tax exemption in the form
prescribed by law.

     

    1.7.
Additional Documents. The Holder
will sign any and all documents required by law, the Company’s ByLaws and/or
any agreement to which the Company is a party or by which it
bound, to facilitate the issuance of stock upon exercise of this
Warrant.

     

    1.8.
Loss or Destruction of Warrant.
Upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant, and (in the
case
of loss, theft or destruction) of reasonable expense reimbursement and
satisfactory

     

    
      
        
        

      

      
        - 3
-

        
          

        

      

      
        
        

      

    

     

    indemnification,
and upon surrender and cancellation of this Warrant, if mutilated, the Company
will execute and deliver a new Warrant of like tenor and date.

     

    
      	
              2.

            	
              RESERVATION
      OF STOCK; PRESERVATION OF RIGHTS OF
HOLDER

            

    

     

    2.1.
Reservation of Shares. The
Company hereby agrees that, at all times prior to the expiration
or exercise of this Warrant, it will maintain and reserve, free from
pre-emptive
or similar rights, such number of authorized but unissued shares of Common
Stock
so that this Warrant may be exercised without additional authorization of
Common
Stock after giving effect to all other warrants, convertible securities and
other rights
to acquire shares of the Company.

     

    2.2.
Preservation of Rights. The
Company will not, by amendment of its organizational documents
or through reorganization, recapitalization, consolidation, merger, dissolution,
transfer of assets, issue or sale of securities or any other voluntary act,
avoid or
seek to avoid the observance or performance of any of the covenants,
stipulations, conditions
or terms to be observed or performed hereunder, but will at all times in good
faith
assist in the carrying out of all the provisions hereof and in taking of all
such actions
and making all such adjustments as may be necessary or appropriate in order to
fulfill
the provisions hereof.

     

    
      	
              3.

            	
              ADJUSTMENT

            

    

     

    3.1.
Adjustments. The number of
Warrant Shares purchasable upon the exercise of this Warrant
and the payment of the Exercise Price shall be subject to adjustment from time
to time or
upon exercise as provided in this Section 3.

     

    3.2.
Bonus Shares. In the event that
during the Warrant Period the Company shall distribute a
stock dividend or shares pursuant to a reclassification of its share capital to
all of the stockholders
of the Company (i.e., bonus shares) or issue rights, option or warrants for
its
Common Stock at below market price to all of the Company's stockholders, then
this Warrant
shall represent the right to acquire, in addition to the number of Warrant
Shares indicated in the caption of this Warrant, the amount of such bonus shares
andlor to receive the stock dividends, without payment of any additional
consideration therefor, to which the Holder would have been entitled had this
Warrant been exercised prior to the distribution of the stock dividends or the
bonus shares. Any adjustment made pursuant to this subsection 3.2 shall become
effective immediately after the effective date of such event retroactive to the
Closing Date (as defined in the Subscription Agreement). Whenever the number of
Warrant Shares purchasable upon the exercise of the Warrant is adjusted, as
herein provided, the Exercise Price payable upon the exercise of such Warrant
shall be adjusted by multiplying such Exercise Price immediately prior to such
adjustment by a fraction, the numerator of which shall be the number of Warrant
Shares purchasable upon the exercise of the Warrant immediately prior to such
adjustment, and the denominator of which shall be the number of Warrant Shares
so purchasable immediately thereafter.

     

    
      
        
        

      

      
        - 4
-

        
          

        

      

      
        
        

      

    

     

     

    3.3.
Consolidation and Division. In
the event that during the Warrant Period the Company consolidates
its share capital into stock of greater par value, or subdivides them into
stock
of lesser par value, then the number of Warrant Shares to be allotted on
exercise of this
Warrant after such consolidation or subdivision shall be reduced or increased
accordingly,
as the case may be, such increase or decrease, as the case may be, to
become
effective immediately after the opening of business on the day following the day
upon
which such subdivision or combination becomes effective, and in each case the
Exercise
Price shall be adjusted appropriately such that the aggregate consideration
hereunder
to the Company shall not change.

     

    3.4.
Capital Reorganization.
In the event that during the Warrant Period a reorganization of
the
share capital of the Company is effected (other than subdivision, combination or
reclassification
provided for elsewhere in this Section 3) and the shares of Common Stock
are exchanged for other securities of the Company, then, as part of such
reorganization,
provision shall be made so that the Holder shall be entitled to purchase
upon
exercise of this Warrant such kind and number of shares or other securities of
the Company
to which the Holder would have been entitled had this Warrant been exercised
prior
to such reorganization, and such that the aggregate consideration to the Company
hereunder
shall not change.

     

    3.5.
If at any time the Company shall distribute a dividend in liquidation or partial
liquidation or
by way of return of capital, or a dividend regardless of whether or not payable
out of earnings
or surplus legally available for dividends, the Exercise Price shall be reduced
by
an amount equal to the Dollar equivalent of the per-share distribution on the
record date fixed for the purpose of such distribution.

     

    3.6.
In the event that the Company shall consolidate with or merge with or
into another corporation
or convey all or substantially all of its assets to another corporation or other
entity,
then, in each such case, the Holder, upon any exercise of this Warrant, at any
time after
the consummation of such consolidation, merger, or conveyance, shall be entitled
to
receive, in lieu of the Warrant Shares receivable upon the exercise of the
Warrant prior
to such consummation, the shares or other securities or property to which such
Holder
would have been entitled upon the consummation of such consolidation, merger
or
conveyance if the Holder had exercised the Warrants immediately prior thereto,
all subject
to further adjustment as provided in this Section 3, and the successor or
purchasing
corporation or other entity in such consolidation, merger or conveyance (if
not
the Company) shall duly execute and deliver to the Holder a supplement hereto
acknowledging
such corporation's or entity's obligations under the Warrant; and in each
such
case, the terms of the Warrant (including the exercisability, transfer and
adjustment provisions
of the Warrant) shall be applicable to the shares or other securities or
property receivable
upon the exercise of the Warrant after the consummation of such consolidation,
merger or conveyance.

     

    3.7.
Adjustment due to Future Issuance of
Securities.

     

    3.7.1.
Full Ratchet Anti-Dilution
Protection. Until such time in which an aggregate amount
of US$ 15,000,000 has been invested in the Company (excluding the

     

    
      
        
        

      

      
        - 5
-

        
          

        

      

      
        
        

      

    

     

    Execution
Copy

     

     

    Excluded
Capital, as defined in the Subscription Agreement), in any event that the
Company issues any additional securities to the Purchaser or any third party,
save for Excluded Issuances (as defined in the Subscription Agreement), at a
purchase price, conversion price or exercise price per share less than the
Exercise Price, the Holder will benefit from a “full ratchet” anti-dilution
protection, such that the Exercise Price shall be retroactively from the Closing
Date (as defined in the Subscription Agreement) reduced to the lowest price per
share at which such additional securities shall have been issued.

     

    3.7.2.
Most Favored Terms. Until such
time as an aggregate amount of US$ 15,000,000 has been invested in the Company
(excluding the Excluded Capital), in the event that the Purchaser or any third
party is issued shares or securities convertible into shares of the Company
under terms more favorable than those set forth in this Warrant, then, at the
option of the Holder, this Warrant shall be construed as containing the more
favorable terms afforded to such third party, as though such terms were
previously provided herein retroactively from the Closing Date (as defined in
the Subscription Agreement). For example, if warrants are offered at a higher
exercise price but at higher coverage to funds raised (over 100%) and or for a
term exceeding 5 years, then the number of Warrants under this Agreement will be
retroactively increased to equal such higher warrant coverage or its term will
be extended, as applicable. All other terms of the Warrant shall remain in
effect.

     

    3.8.
Any dispute on matters under Section 3.2, 3.3, 3.4 and/or 3.7 shall be referred
to a resolution
by Giza Singer Even and Kesselman and Keselman (PWC Israel). In the event
of
different determinations by Giza Singer Even and PWC, the dispute shall be
resolved by
calculating the average between the values determined by each of Giza Singer
Even and
PWC with respect to each parameter of their determination. The determination of
Giza
Singer Even and PWC will be exclusive and final. The non-prevailing party in
such dispute
shall bear the expenses of Giza Singer Even and PWC. The Company hereby
acknowledges
that the Purchaser and its affiliates retain the services of Giza Singer Even
and
PWC in the ordinary course of business for various tasks (including, but not
limited to,
accounting, tax, financial and fairness opinion, advisory services and the like)
and that
they will not be limited from retaining them also in the future. In that
respect, the Company
waives any claim it may have against the Purchaser and its affiliates in
connection
with a conflict of interest regarding the matters contemplated in this Section
3.8.

    
       

      4. 
NOTICE OF CERTAIN
EVENTS

    

     

    If
at any time during the Warrant Period (i) there shall be any capital
reorganization or reclassification of the stock capital of the Company or any
other event set forth in Section 3
above; (ii) the Company shall consolidate with or merge with or into
another corporation or convey all or substantially all of its assets to another
corporation or other entity; or (iii) there shall be a voluntary or involuntary
dissolution, liquidation or winding up of the Company, then, in any one or more
of said events, the Company shall deliver to the Holder prior written notice
thereof, including the date on which (a) a record shall be taken in connection
with such event and (b) the consummation date of such event. Such written notice
shall be delivered to the Holder at

     

    
      
        
        

      

      
        - 6
-

        
          

        

      

      
        
        

      

    

     

    least
thirty (30) days prior to the consummation of the applicable event and not less
than thirty (30) days prior to the record date in respect thereto (subject to
the provisions of Section 7 herein).

     

    
      5. 
NOTICE OF
ADJUSTMENTS

    

     

    Whenever
an adjustment pursuant to Section 3 above is effected, the Company shall
promptly compute such adjustment and deliver to the Holder a certificate setting
forth the number of Warrant Shares (or any other securities) for which this
Warrant is exercisable and the Exercise Price as a result of such adjustment, a
brief statement of the facts requiring such adjustment and the computation
thereof and when such adjustment has or will become effective.

     

    
      6. 
RIGHTS OF THE
HOLDER

    

     

    The
Holder acknowledges that the Warrant Shares shall be subject to such certain
rights, privileges, restrictions and limitations as set forth in this Warrant
and the Certificate of Incorporation or ByLaws of the Company, as may be amended
from time to time. The Holder further acknowledges that the Warrant Shares are
not listed for trading and therefore the sale and transfer thereof are subject
to further limitations. This Warrant shall not entitle the Holder, by virtue
hereof, to any voting rights or other rights as a stockholder of the Company,
except for the rights expressly set forth herein.

     

    
      7. 
TERMINATION

    

     

    Notwithstanding
anything to the contrary, this Warrant and all the rights conferred hereby shall
terminate and expire at the aforementioned time on the last day of the Warrant
Period.

     

    
      8. 
MISCELLANEOUS

    

     

    8.1.
Entire Agreement;
Amendment. This Warrant, the Subscription Agreement and the
other
Transaction Documents (as defined in the Subscription Agreement) set forth the
entire
understanding of the parties hereto with respect to the subject matter hereof
and supersedes
all existing agreements among them concerning such subject matter. All
article
and section headings herein are inserted for convenience only and shall not
modify
or affect the construction or interpretation of any provision of this Warrant.
No modification
or amendment of this Warrant will be valid unless executed in writing by
the
Company and the Holder.

     

    8.2.
Waiver. No failure or
delay on the part of any of the parties hereto in exercising any
right,
power or privilege hereunder and/or under any applicable laws or the exercise of
such
right or power in a manner inconsistent with the provisions of this Warrant or
applicable
law shall operate as a waiver thereof. Any waiver must be evidenced in
writing
signed by the party against whom the waiver is sought to be
enforced.

     

    8.3.
Successors and Assigns;
Assignment. This Warrant shall inure to the benefit of, be binding
upon, and be enforceable by the Holder and its respective successors, assigns,
and
administrators. Either party may freely assign or transfer the rights granted
pursuant to
this Warrant. If, as a result of such assignment by the Purchaser, the Company
is

     

    
      
        
        

      

      
        - 7
-

        
          

        

      

      
        
        

      

    

     

    required
under applicable law to file any registration statement or prospectus with the
US Securities and Exchange Commission or any stock exchange or other similar
institution in any jurisdiction, that the Company would not be required to file
under the Subscription and Registration Rights Agreement, the party that seeks
such assignment will cover the Company's expenses for such filing. Upon the
request of the Holder, and subject to the approval of the Company’s General Meeting
to be convened as soon as practicable following the date of the Subscription and
Registration Rights Agreement to approve the transactions contemplated herein,
in the Subscription and Registration Rights Agreement and in the Convertible
Debenture, the Company shall cancel a portion of the Warrant (as solely
determined by the Holder), and shall grant, in lieu thereof, to the person
designated by the Holder an option to purchase such amount of Warrant Shares as
determined by the Holder on the same terms of the Warrant except that if the
holder shall be a director of the Company or shall otherwise be eligible for
Section 102 treatment, such option shall be granted under Section 102 of the
Israeli Income Tax Ordinance.

     

    8.4.
Governing Law. Except as
explicitly set forth herein, this Warrant shall be governed
by and construed under the laws of the State of Israel, without regard
to
the conflicts of laws provisions thereof. Any dispute arising in connection
with
this Warrant shall be settled exclusively before the competent courts of the
city
of Tel-Aviv-Jaffa.

     

    8.5.
Notices. Any notice required or
permitted to be given to a party pursuant to the provisions
of this Warrant will be in writing and will be effective and deemed delivered
to
such party on the earliest of the following: (a) all notices and other
communications delivered
in person or by courier service shall be deemed to have been delivered as of
actual
delivery thereof; or, (b) those given by facsimile transmission shall be deemed
delivered
on the following business day after transmission, with confirmed transmission
thereof;
or (c) all notices and other communications sent by registered mail (or air mail
if the
posting is international) shall be deemed given seven (7) days after posting:
All notices shall be addressed as set
forth below or at such other address as the party shall have
furnished to the other party in writing in accordance with this
provision:

     

    8.5.1.
If sent to the Company to:

    8
Hartom St. Har Hotzvim 

    Jerusalem
97775 

    Fax:
02-5486550

    Email:
avi.barak@biocancell.com

    Attention:
Avi Barak

     

    with
a copy (which shall not constitute notice) to:

     

    
      
        
        

      

      
        - 8
-

        
          

        

      

      
        
        

      

    

     

    Yuval
Horn, Adv.

    Baratz,
Horn &
Co.

    1
Azrieli Center

    Tel
Aviv, Israel 67021 

    Fax:
+972-3-6960986

    Email:
y.horn@bar-1aw.com

     

    8.5.2.
If sent to the Purchaser to: [______________]

     

    
    

    8.6.
Severability. If any provision
of this Warrant is held to be unenforceable, this Warrant shall
be considered divisible and such provision shall be deemed inoperative to the
extent
it is deemed unenforceable, and in all other respects this Warrant shall remain
in full
force and effect; provided, however,
that if any such provision may be made enforceable
by limitation thereof, then such provision shall be deemed to be so limited
and
shall be enforceable to the maximum extent permitted by applicable
law.

     

    8.7.
Counterparts. This Warrant may
be executed in any number of counterparts, each of which
shall be an original, but all of which together shall constitute one instrument.
Facsimile
signatures of a party shall be binding as evidence of such party's agreement
hereto
and acceptance hereof.

     

     

    [THE
REMAINDER OF THIS PAGE WAS INTENTIONALLY LEFT BLANK]

     

     

    
      
        
        

      

      
        - 9
-

        
          

        

      

      
        
        

      

    

     

     

    IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its
officer thereunto duly authorized.

     

     

    
      
        	Dated:
      [____________]  	BIOCANCELL THERAPEUTICS
      INC.	 
	 	 	 	 
	
                 

              	
                By:
      

              	 	 
	 	 	Name: 	 
	 	 	Title: 	 
	 	 	 	 

      

    

     

     

     

     

    AGREED
AND ACCEPTED:

     

     

    By:____________________________

          Name:

         
Title:

     

    
      
        
        

      

      
        - 10
-

        
          

        

      

      
        
        

      

    

     

     

    Exhibit
A

     

    Exercise
Notice

    Date:
________

     

     

     

    To:
BioCancell Therapeutics Inc.

     

     

    The
undersigned, pursuant to the provisions set forth in the Warrant to which this
Exercise Notice is attached (the “Warrant”), hereby elects
to purchase of the Warrant Shares (as such term is defined in the
Warrant).

     

     

    Signature:

     

     

    Address:
_________________________

     

     

                     
_________________________

     

     

                      _________________________Unassociated Document

    
      EXHIBIT 10.1(i)

       

      EXCLUSIVE
LICENSE AGREEMENT

       

      THIS
AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT (the “Agreement”) is made in Jerusalem as of this _
day of November 14, 2005 (the “Effective Date”).

       

      BETWEEN:

       

      YISSUM
RESEARCH DEVELOPMENT COMPANY OF THE

      HEBREW
UNIVERSITY OF JERUSALEM

       

      (hereinafter
referred to as “Yissum”)

       

      AND

       

      BIOCANCELL
THERAPEUTICS INC.

      A company incorporated under the laws
of the State of Delaware

      (formerly known as DBT
Biopharmaceuticals Inc.)

      (hereinafter referred to as
“DBTI”)

       

      AND

       

      BIOCANCELL
THERAPEUTICS LTD.

      a company
established under the laws of the State of Israel

      formerly
known as DBT Biopharmaceuticals Ltd.)

      (hereinafter
referred to as “DBTL”)

       

      (DBTI and
DBTL collectively hereinafter referred to as the “Company”)

       

      WHEREAS Yissum is the owner of
certain rights, title and interest in and to the Licensed Technology (defined
below); and

       

      WHEREAS Yissum and the Company
entered into that certain Exclusive License Agreement dated November 17, 2004
pursuant to which Yissum granted to Company an exclusive worldwide license with
rights to grant sublicenses and sub-sublicenses under the Licensed Technology
(the “Original
Agreement”);
and

       

      WHEREAS Yissum and the Company
wish to amend and restated in full the Original Agreement entered into that
certain Exclusive License, in the form set forth herein.

       

      NOW, THEREFORE, for and in
consideration of the premises and other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, Yissum and Company
(hereinafter individually as a “Party”; and collectively as the “Parties”)
expressly agree as follows.

      
        
           

        

        
           

          
            

          

        

        
           

        

      

       

      SECTION
1

      Recitals and
Definitions

       

      In this
Agreement the following expressions shall have the corresponding meanings,
unless the context otherwise requires:

       

      “Affiliate” shall mean any
corporation, partnership, or other entity that at any time during the term of
this Agreement directly through one or more intermediaries Controls or is
Controlled by or is under common Control with a party to this Agreement, but
only for so long as the relationship exists. A corporation or other entity shall
no longer be an Affiliate when through loss, divestment, dilution or other
reduction of ownership, the requisite Control no longer exists.

       

      “Control” or “Controls” or “Controlled” shall mean: (i) in the
case of a corporation, ownership or control, directly or indirectly, of more
than fifty percent (50%) of the shares of stock entitled to vote for the
election of directors; or (ii) in the case of an entity other than a
corporation, ownership or control, directly or indirectly, of more than fifty
percent (50%) of the assets of such entity.

       

      “First Commercial Sale” means in each country,
the date the Licensed Product is first sold, marketed, or otherwise made
publicly available for sale. Licensed Products that are distributed or used
solely for pre-clinical studies, clinical trials, treatment IND purposes or any
other similar use prior to receiving regulatory approval by the relevant
regulatory authority shall not be considered sold, marketed or made publicly
available for sale and shall not constitute First Commercial Sale
hereunder.

       

      “Licensed Product” shall mean any product
the manufacture, use, sale or importation of which is covered by a Valid
Claim.

       

      “Licensed Technology” shall mean the Patents,
and any technology, trade secrets, methods, processes, know-how, show-how,
formulas, data, information, inventions, improvements, discoveries or results
relating to the Patents, whether patentable or otherwise. Any future patents,
technology, trade secrets, methods, processes, know-how, show-how, formulas,
data, information, inventions, improvements, discoveries or results, relating to
the Patents whether or not patentable, will also be considered as Licensed
Technology.

       

      “Net Sales” shall mean the gross
amount invoiced by Company or Affiliates to third parties, which are not
Sublicensee(s), from sales of Licensed
Products in an arm’s length transaction, less (i) discounts allowed in amounts
customary in the trade for quantity purchases, cash payments, or prompt
payments, to wholesalers and distributors; (ii) sales, tariff duties and/or use
taxes directly imposed and with reference to particular sales, including VAT;
(iii) outbound transportation prepaid or allowed, amounts allowed or credited on
returns, export licenses, import duties, and prepaid freight; (iv) amounts not
actually collected by reason of rejection, return of goods, and retroactive price
reductions; and (iv) Third Party Royalties. No deductions shall be made for
commissions paid to individuals whether they are with independent sales agencies
or regularly employed by Company and on its payroll or for cost of collections.
In the event of sales not made at “arm’s length”, Net Sales shall be calculated
in accordance with arm’s length prices determined by current market conditions.
Yissum will have to establish that sales are not made at arm’s length on the
basis of adequate documentary evidence. Net Sales occur when a Licensed Product
is invoiced. Notwithstanding the immediately preceding sentence, distribution or
sales of Licensed Products by Company to its Affiliates shall not be deemed to
be Net Sales unless such Affiliate is the final end user of such Licensed
Products.

      
        
           

        

        
           

          
            

          

        

        
           

        

      

       

      “Patents” shall mean the patents
set forth on Appendix
1 attached hereto, together with any and all registered patents covering
Licensed Technology granted whether in the United States of America or any other
country, including any and all substitutions for and divisions, continuations,
continuations-in-part, provisionals, and non-provisionals, renewals, reissues,
any foreign patent applications and divisionals or national phase applications
which claim priority of any application which issued into one of the patent
applications set forth in Appendix 1.

       

      “Research” shall mean the continued
research regarding the Licensed Technology to be conducted pursuant to the
Research Plan.

       

      “Research Plan” shall mean the
description of the conduct of the Research as attached to this Agreement as
Appendix II.

       

      “Research Results” shall mean the Research,
including any patents, patent applications, information, material, results,
devices and know-how arising therefrom.

       

      “Sublicensee(s)” shall mean any third
party to whom Company has granted a sublicense under the Licensed Technology to
manufacture, develop, distribute and market Licensed Products consistent with
the provisions of this Agreement.

       

      “Sublicensing Revenue” shall mean all cash,
sublicensing fees, running royalties and other consideration paid to Company by
Sublicensee(s) in consideration for the granting of rights to the Licensed
Product and/or Licensed Technology and in connection therewith. Sales of
Licensed Products from Company to Sublicensee(s) shall not be deemed to be
Sublicensing Revenue provided that such Sublicensee(s) is/are not the final end
user of the Licensed Products. Notwithstanding the above, Sublicensing Revenues
shall exclude (a) payments used or reimbursed for research, (b) payments used or
reimbursed for parent costs, and (c) payments received from the issuance of debt
or equity securities of the Company.

       

      “Third Party Royalties” royalties calculated on
any amount invoiced by the Company in connection with the sale of a Licensed
Product and actually paid by the Company to a third party for the right to use
patents or other intellectual property rights of such third party, without which
right of use the Company would not be entitled to develop, manufacture and sell
such Licensed Product; provided that the duty to pay royalties to such third
party has been established at arm’s-length and in good faith and is set out in a
written agreement; and

      
        
           

        

        
           

          
            

          

        

        
           

        

      

       

      “Valid Claim” shall mean (i) a claim
of an issued Patents which has not expired and which has not been held revoked,
invalid or unenforceable by decision of a court or other governmental agency of
competent jurisdiction, unappealable or unappealed with the time allowed for
appeal having expired, and which has not been admitted to be invalid through
reissue or disclaimer or otherwise; or (ii) any claim of a pending patent
application covering the Licensed Technology, which was filed in good faith and
which has been prosecuted with due diligence.

       

      SECTION 2

      Grant of
License

       

      2.1           Subject
to the terms of this Agreement, Yissum hereby grants to Company an exclusive,
worldwide right and license under the Licensed Technology to develop, have
developed, make, have made, use, manufacture, market, sell, have sold, offer to
sell, commercialize, import, export, sublicense, sub-sublicense and distribute
Licensed Products and/or provide services relating thereto (the “License”).

       

      2.2           Company
shall have the exclusive right to enter into sublicense agreements with respect
to the Licensed Technology. All sublicenses granted by Company hereunder shall
be subject to this Agreement in all respects. Each such sublicense agreement
shall include a requirement that the Sublicensee use its commercially reasonable
efforts to bring the subject matter of the sublicense into commercial use. No
sublicense shall relieve Company of any of its obligations under this Agreement.
Company shall forward to Yissum a complete copy
of each sublicense
agreement (including, without limitation, all amendments and addenda thereto)
granted hereunder within thirty (30) days after execution of such agreement by
the parties thereto. In the event that Company has granted more than one
sublicense, any breach by one Sublicensee will not effect any other
non-breaching Sublicensee(s), such way that the License and the sublicense in
respect of any non-breaching Sublicensee(s) is not effected.

       

      2.3           Notwithstanding
Section 2.1, not later than December 31, 2005 Company shall determine (the
“Determination”): (i) to which of either DBTI or DBTL
the License shall be granted (the “DBT Licensee”), or (ii) which indications or
components of the Licensed Technology shall be granted on an exclusive basis to
DBTI and which shall be granted on an exclusive basis to DBTL. Within ten (10)
days of the Determination, Company shall provide written notice to Yissum of its
determination as aforesaid. Upon the provision of such notice, the License shall
be automatically modified to reflect the Determination and the terms of this
Agreement shall be modified mutatis
mutandis to give effect
thereto.

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

       

      SECTION
3

      Royalties and
Reporting

       

      3.1           In
consideration of the License granted hereunder, Company shall pay royalties to
Yissum in the manner hereinafter provided (the “Royalties”). Company shall pay to
Yissum:

       

      (i)             Five
percent (5%) of Net Sales; and

       

      (ii)            For
Sublicensing Revenues of up to $30,000,000 per year – Ten Percent (10%);
and

       

      (iii)           For
Sublicensing Revenues above $30,000,000 per year – Six and One Half Percent
(6.5%).

       

      3.2           Sixty
(60) days after the end of each 6 month period commencing from the date of the
First Commercial Sale, Company shall furnish Yissum with a bi-annual report
(herein the “Periodic
Report”) detailing the total sales effected
during the reporting period and the total Royalties and Sub-license Revenues due
to Yissum in respect of that period.

       

      3.3           The
Periodic Reports shall state details of Net Sales and Sublicensing Revenues,
including the country in which the sale was made, the number of Licensed
Products, the aggregate Net Sales and Sublicensing Revenues during the period
covered by the report and resulting Royalties due to Yissum for such completed
year.

       

      3.4           On
the date prescribed for the submission of each Periodic Report, Company shall
pay the Royalties and amounts due to Yissum in accordance with the Periodic
Report.

       

      3.5           The
value of each sale shall be computed on the date of sale in US Dollars based on
the rates published in the Wall Street Journal. The Royalties shall be computed
and paid in US dollars. Payment of Value Added Tax (if applicable) shall be
added to each payment in accordance with the statutory rate in force at such
time. In event that Company is prohibited under applicable foreign currency laws
to transact in US Dollars, payment shall be made in New Israeli Shekels
according to the representative rate of exchange prevailing on the date of
payment. Subject to applicable law, Company shall be entitled to withhold and
deduct from any payment made herein to Yissum any and all taxes as required by
law, and such withheld or deducted amount shall be treated as paid over to
Yissum for purposes of this Agreement, unless Yissum provides Company with an
appropriate withholding exemption certificate. Any sum of money due to Yissum
hereunder which is not duly paid shall bear interest from the due date of
payment until the actual date of payment at the maximum rate of default interest
prevailing at Bank Leumi in respect of US dollar lines of credit.

       

      3.6           Company
shall keep full and correct books of accounts in accordance with General
Accepted Accounting Procedures as required by U.S. Accounting Standards enabling
the Royalties to be calculated. Company shall procure that Sublicensee(s), if
any, also keep such books of accounts as aforesaid. Company shall submit to
Yissum a report containing all the particulars mentioned in Section 3.3 above in
respect of each Periodic Report detailing the Royalties and Sublicensing
Revenues due to it in respect of the period covered by the Periodic Report. An
annual report, authorized by a certified public accountant, shall be submitted
not later than sixty (60) days following the end of each calendar
year.

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

       

      3.7           For
five years following the end of the calendar year to which a Periodic Report
pertain, Yissum may appoint an independent public accountant to examine
Company’s and Sublicensee(s)’ books of accounts and any report or information
relating to the manufacture, marketing, distribution and sale of the Licensed
Products in order to verify the calculation of the Royalties and Sublicensing
Revenue and the accuracy of the information given to Yissum in the aforegoing
reports. Such examination shall be made at Company’s place of business during
ordinary business hours with at least fifteen (15) days prior written notice. If
an error greater than five percent (5%) in the reports of Company will be found,
Company will bear the full cost of the examination. Company shall reasonably
ensure that Yissum is able to exercise its rights pursuant to this section
regarding Sublicensee(s).

       

      SECTION
4

      Development;
Commercialization and Research

       

      4.1           Company
undertakes, at its own expense, to use its commercially reasonable efforts to
carry out the development work necessary to develop and commercialize the
Licensed Technology.

       

      4.2           Company
shall provide Yissum with annual reports which shall detail the development
results and other related work effected by Company during the twelve (12) months
prior to the report.

       

      4.3           Company
shall give Yissum written notice of the First Commercial Sale within thirty (30)
days thereof.

       

      4.4            (i)           Yissum
shall procure the conduct of the Research at the Laboratory of Prof. Abraham
Hochberg and under his supervision and in accordance with the Research Plan.
Company undertakes to finance the performance of the Research in accordance with
the budget forming part of the Research Plan.

       

      (ii)           Yissum
shall procure that Company be provided with quarterly reports detailing the
results and conclusions of the Research. Yissum shall procure that appropriate
records of the Research are kept in sufficient detail and in good scientific
manner.

       

      (iii)           The
initial period of the Research shall be for two years and the parties may agree
to extend this period. Company may cease the financing of the Research upon a
written notice to Yissum of at least 90 days prior to the cessation of
financing. In the event of cessation of financing of the Research, Company shall
reimburse Yissum for: (a) all expenses incurred in relation to the Research
prior to the notice of cessation of the financing of the Research; and (b) all
committed outstanding expenses and obligations payable subsequent to the notice
of cessation of the financing, provided such outstanding expenses and
obligations were incurred prior to the notice of cessation.

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

       

      SECTION
5

      Ownership

       

      All
rights in and to the Licensed Technology shall be owned by Yissum, and Company
shall hold the rights granted pursuant to the License hereunder and make use of
them exclusively in accordance with the terms of this Agreement. The Research
Results resulting from Research conducted in accordance with Section 4.4 shall
be exclusively owned by Yissum, shall form part of the Licensed Technology and
shall be licensed to the Company under the same terms and conditions of this
Agreement.

       

      SECTION
6

      Patents

       

      6.1           Company
shall assume full responsibility for and conduct patent prosecution and
maintenance of the Patents and will be responsible for preparing, filing,
prosecuting and maintaining all Patents and shall use patent counsel of its own
choice, subject to the approval of Yissum (such approval not to be unreasonably
withheld), at Company’s own expense. In the time period until the first round of
financing by Company, the decisions regarding preparing, filing, prosecuting and
maintaining all patents will be accepted mutually by Company and Yissum, after
this time period, these decisions will borne only by Company. Company agrees to
pay all costs, incident to the United States and foreign applications, patents
and like protection, including all costs incurred for filing, prosecution,
issuance and maintenance fees as well as any costs incurred in filing
continuations, continuations-in-part, divisional or related applications and any
re-examination or re-issue proceedings. Company shall file and maintain patent
applications corresponding to the Licensed Technology in such countries as
Company in its sole discretion shall select but shall notify and consult with
Yissum as to those countries where it shall not file and maintain patent
applications. Upon the completion of Company’s first round of financing of an
amount of at least $2,500,000 (the “Financing”), Company hereby undertakes to
reimburse Yissum for previous documented expenses and costs incurred by Yissum
up to 2005 relating to the filing, maintenance and prosecution of the Patents
not to exceed $50,000. Company shall pay such reimbursement in eight (8) equal
quarterly installments commencing ninety (90) days from the date of the
Financing.

       

      6.2           Company
agrees to keep Yissum informed of filing and prosecutions pursuant to this
Section 6 including submitting to Yissum copies of all official actions, all
relevant correspondence with the patent attorneys, applications, continuations,
re-examinations, re-issues, divisionals or like proceedings and responses
thereto. Company shall consult with Yissum regarding any abandonment of the
prosecution of patents application within the Patents.

       

      6.3           Each
and every patent application as aforesaid in relation to the Licensed Technology
shall be registered exclusively in the name of Yissum at Company’s sole expense,
and shall be included automatically within the scope of the License granted
pursuant to the terms of this Agreement.

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

       

      6.4            In
the event that Company decides not to continue prosecution of a Patent
application to issuance or maintain any patent application or patent on
technology within the Patents in a certain jurisdiction, Company shall timely
notify Yissum in writing in order that Yissum may continue said prosecution or
maintenance of such applications at its option and at its own
expense in such jurisdiction. In the event that (i) Company elects not to file
or not to prosecute
or to discontinue or to abandon the filing, prosecution and/or maintenance of
the Patents in certain countries (the “Abandoned Countries”) and (ii) Yissum
decides to do so at its expense, then (iii) Yissum shall notify Company in
writing of its intention to file, prosecute and/or maintain a patent and Company
shall have a ninety (90) day period to decide whether it wishes to bear the
expenses of such actions. In the event the Company shall notify Yissum that it
does not wish to bear the costs of such filing, maintenance and/or prosecution
or in absence of a reply from the Company within the ninety (90) day period, the
License shall no longer be applicable in the Abandoned Countries.

       

      It is
hereby clarified, if Company fails to notify Yissum in a timely manner as
required hereunder, which, for the purpose of this section, shall be the time,
considered reasonably, that would enable Yissum to effectively carry out such
filing, prosecution or maintenance of the Patents, Company shall be considered
in default of this Agreement.

       

      6.5           Company
and its Sublicensee(s) shall mark all products covered by Patents with patent
numbers in accordance with the statutory requirements in the country(ies) of
manufacture, use, and sale, and pending the issue of any patents. Company shall
ensure that its Sublicensee(s) comply with the provisions of this
section.

       

      6.6           Company
undertakes to use commercially reasonable efforts at its own expense to protect
against a third party’s infringement of the Patents and forthwith to advise
Yissum upon learning of the infringement. Company shall give Yissum immediate
notice of any approach made to it by a patent examiner and/or attorney in
connection with the subject matter of this Agreement. Company shall reply to
such approaches after consultation with Yissum.

       

      6.7           Company
shall use its commercially reasonable efforts at its own expense to defend any
action, claim or demand made by any entity in connection with rights in the
Patents and/or patents and shall give notice to Yissum immediately upon learning
of any such action, claim or demand as aforesaid. Any assistance that will be
requested by Company from Yissum for the purpose of defending any action, claim
or demand made by any entity in connection with rights in the Patents and/or
patents, will be provided by Yissum without any additional charge to
Company.

       

      6.8           Any
settlement, consent judgment or other voluntary final disposition of any action
pursuant to the provisions of this section, shall not be entered into without
consultation with Yissum and the prior written consent of Yissum which shall not
be reasonably withheld or delayed.

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

       

      6.9           Subject
to reimbursement of documented reasonable out-of-pocket expenses incurred by
Company in relation to any legal action contemplated under the provisions of
this section, any award in favor of Yissum and/or Company resulting from such
legal action shall be divided by Yissum and the Company pursuant to Section 3.1
as if such award was Sublicensing Revenues. Any recovery of damages by Company
for each such suit shall be applied first in satisfaction of any unreimbursed
documented reasonable expenses and legal fees of Company relating to such
suit.

       

      SECTION
7

      Confidentiality

       

      7.1           Licensor
Confidential Information. Company agrees that, without the prior written
consent of Yissum, in each case, during the term of this Agreement, and for
three (3) years thereafter, it will keep confidential, and not disclose or use
Yissum Confidential Information (as defined below) other than for the purposes
of this Agreement or as detailed below. Company shall treat such Yissum
Confidential Information with the same degree of confidentiality as it keeps its
own confidential information, but in all events no less than a reasonable degree
of confidentiality. Company may disclose the Yissum Confidential Information
only to employees, consultants or researchers of Company or of its affiliates
who have a “need to know” such information in order to enable Company to
exercise its rights or fulfill its obligations under this Agreement and provided
such parties are legally bound by agreements which impose confidentiality and
non-use obligations comparable to those set forth in this Agreement. For
purposes of this Agreement. “Yissum Confidential Information” means any
scientific, technical, trade or business information relating to the subject
matter of this Agreement designated as confidential or which otherwise should
reasonably be construed under the circumstances as being confidential disclosed
by or on behalf of Yissum, or any of its employees, consultants or researchers
to Company, whether in oral, written, graphic or machine-readable
form, except to the extent such information:
(i) was known to Company at the time it was disclosed, other than by previous
disclosure by or on behalf of Yissum or any of its employees, consultants or
researchers, as evidenced by Company’s written records at the time of
disclosure; (ii) is at the time of disclosure or later becomes publicly known
under circumstances involving no breach of this Agreement; (iii) is lawfully and
in good faith made available to Company by a third party who is not subject to
obligations of confidentiality to Yissum with respect to such information; (iv)
is independently developed by Company without the use of or reference to Yissum
Confidential Information, as demonstrated by documentary evidence, or (v) is
disclosed pursuant to a court or administrative order, provided however that
Company will first notify Yissum of any such order and afford Yissum the
opportunity to seek a protective order relating to such disclosure.

       

      Notwithstanding
anything to the contrary in this Section 7.1, Company may disclose Yissum
Confidential Information to actual and potential business partners,
collaborators, investors, contractors, service providers and consultants,
provided, in each case, that such recipient of Confidential Information first
enters into a legally binding agreement with Company which imposes
confidentiality and non-use obligations with respect to Confidential Information
comparable to those set forth in this Agreement for a period of at least five
(5) years from the date of disclosure of Yissum Confidential Information to such
recipient.

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

       

      7.2           Company Confidential Information.
Yissum agrees that, without the prior written consent of Company, in each
case, during the term of this Agreement, and for three (3) years thereafter, it
will keep confidential, and not disclose or use Company Confidential Information
(as defined below) other than for the purposes of this Agreement. Yissum shall
treat such Company Confidential Information with the same degree of
confidentiality as it keeps its own confidential information, but in
all events no less than a reasonable degree of confidentiality. Yissum may
disclose the Company Confidential Information only to employees, consultants or
researchers of Yissum or its affiliates who have a “need to know” such
information in order to enable Yissum to exercise its rights or fulfill its
obligations under this Agreement and provided such parties are legally bound by
agreements which impose confidentiality and non-use obligations comparable to
those set forth in this Agreement. For purposes of this Agreement. “Company
Confidential Information” means any scientific, technical, trade or business
information relating to the subject mailer of this
Agreement designated as confidential or which otherwise should reasonably be
construed under the circumstances as being confidential disclosed by or on
behalf of Company whether in oral, written, graphic or machine-readable form,
except to the extent such information: (i) was known to Yissum at the time it
was disclosed, other than by previous disclosure by or on behalf of Company as
evidenced by Yissum’s written records at the time of disclosure; (ii) is at the
time of disclosure or later becomes publicly known under circumstances involving
no breach of this Agreement; (iii) is lawfully and in good faith made available
to Yissum by a third party who is not subject to obligations of confidentiality
to Company with respect to such information; (iv) is independently developed by
Yissum without the use of or reference to the Company Confidential Information,
as demonstrated by documentary evidence; or (v) is disclosed pursuant to a court
or administrative order, provided however that Yissum will first notify Company
of any such order and afford Company the opportunity to seek a protective order
relating to such disclosure.

       

      7.3           Each
party may disclose the terms of this Agreement to the extent required, in the
reasonable opinion of such party’s legal counsel, to comply with applicable
laws, as well as to sublicensees and prospective and current investors, pursuant
to appropriate non-disclosure arrangements. If a party discloses this Agreement
or any of the terms hereof in accordance with this Section7.3, such party
agrees, at its own expense, to seek confidential treatment of portions of this
Agreement or such terms, as may be reasonably requested by the other
party.

       

      7.4           Without
prejudice to the aforegoing. Yissum agrees that Company shall have the right to
mention or reference the Hebrew University of Jerusalem’s and/or Yissum’s names
without obtaining Yissum’s prior consent to the extent the use of such names is
reasonably consistent with Company’s obligations pursuant to Section 4.1 hereof.

       

      7.5           The
breach of this section, by any person or entity other than Yissum or Company
shall not be deemed a breach of the Agreement, if Yissum or Company establish
that they took all reasonable steps to avoid such breach.

       

      7.6           The
expiration or termination of this Agreement shall not release the Parties from
their obligations pursuant to this section.

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

       

      7.7      The
provisions of this section shall be subject to permitted publications pursuant
to Section 8 herein.

      

      SECTION
8

      Publications

       

      8.1         Yissum
shall ensure that no publications in writing, in scientific journals or orally
at scientific conventions relating to the Licensed Technology are published by
it or its Researchers. For the purposes of this Agreement, the term
“Researchers” means Pro. Avraham Hochberg and his scientific research group or
other scientific research group whose work is related to the Licensed
Technology.

       

      8.2         Notwithstanding
Section 8.1 above, Yissum may allow the Researchers to publish any research,
research results or know-how relating to the Licensed Technology provided that
it obtains Company’s prior written consent. Company undertakes to reply to any
request by Yissum for Company’s consent within forty-five (45) days of receiving
such request. Company may only decline such request upon reasonable grounds
which shall be fully detailed in writing. In the event that Company does not
reply to such request within the forty-five (45) day period, then Company shall
be deemed to have consented to Yissum’s request to allow the Researchers to
publish in the manner contemplated herein.

       

      8.3         Should
Company decide not to allow publication as provided in Section 8.2 for reasons
which in Yissum’s opinion are unreasonable, acting reasonably, publication shall
be postponed for a period of three (3) months to enable Company to file patent
applications.

       

      8.4         The
provisions of this Section 8 shall not prejudice any other right that Yissum has
pursuant to this Agreement and at law.

       

      8.5         For
the avoidance of doubt, the provisions of this Section 8 in connection with the
prohibition against publication shall not apply to internal publication by
Yissum made in the Hebrew University of Jerusalem for the Researchers and
employees subject to Section 7.

       

      SECTION
9

      Liability and Indemnity

       

      9.1           Except
as set forth herein, Yissum expressly disclaims any and all implied or express
warranties and makes no express or implied warranties of merchantability or
fitness for any particular purpose of the Licensed Technology contemplated by
this Agreement.

       

      9.2           Company
shall be solely liable for any loss, injury and/or damage whatsoever caused to
its employees and/or any person acting on its behalf by reason of Company’s acts
and/or omissions pursuant to this Agreement and/or by reason of any use made of
the Licensed Technology by Company.

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

       

      9.3           Company
undertakes to indemnify, defend and hold harmless (i) Yissum and any person
acting on its behalf and any of its directors, officers, employees and
representatives,
and (ii) the Hebrew University of Jerusalem and any person acting on its behalf
and any of its directors, officers, employees and representatives (herein
referred to as “Indemnitees”) from and against any liability including without
limitation product liability, damages, losses or expenses including reasonable
legal fees and litigation expenses incurred by or imposed upon the Indemnitees
(collectively, “Losses”) only by reason
of Company’s acts and/or omissions and/or which derive from Company’s use,
development, manufacture, marketing, sale and/or sublicensing of the Licensed
Technology except to the extent such Losses are determined to have resulted from
the gross negligence or willful misconduct of Indemnitees.

       

      9.4           Company
shall obtain prior to the commencement of clinical trials by Company and prior
to the First Commercial Sale, comprehensive general liability insurance which
shall provide:

       

      (i)            
product liability coverage,

       

      (ii)           contractual
liability coverage for Company’s indemnification under this Agreement and in
particular as stated in Section 9.3, and

       

      (iii)           Yissum
as an additional named insured.

       

      Upon the
commencement of any clinical trial, Company shall procure and maintain
comprehensive clinical trial liability insurance in amounts commensurate with
accepted commercial practice. All required insurance will be at Company’s sole
cost and expense.

       

      9.5           Company
shall provide Yissum with written evidence of such insurance upon request of
Yissum. Company shall ensure that it maintains on a continuous basis only during
the relevant term of this Agreement the foregoing insurance coverage, and shall
not cancel or terminate such insurance with any insurance provider unless it has
in place alternative coverage consistent with the foregoing. Company shall
provide Yissum with written notice of any material change in such insurance not
later than fifteen (15) days of such change taking effect.

       

      9.6           Company
shall maintain comprehensive general liability insurance beyond the expiration
or termination of this Agreement during the period that a Licensed Product is
being commercialized, distributed or sold by Company and/or any Sublicensee. In
the event of early termination by Yissum, the cost of such general liability
insurance for a period of three (3) months following the date of termination
will he borne by Company and thereafter will be borne by Yissum.

       

      9.7           Yissum
represents and warrants that to the best of its actual knowledge: (i) the
Patents which have been issued and are listed in Appendix 1 are valid
and enforceable: (ii) it has the full power to enter into this Agreement, to
carry out its obligations under this Agreement, and to grant the rights granted
to Company herein; (iii) it has not previously granted and shall not grant to
any third party any rights which are inconsistent with the rights granted to
Company herein, (iv) it has the rights, title, and interest in and to the
Patents, and (v) the
Licensed Technology constitutes all of the intellectual property rights
developed by Prof. Abraham Hochberg laboratory in the Hebrew University in the
field of H19 and IGF2 gene.

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

       

      9.8           Company
represents that: (i) it has full corporate power and authority to enter
into this
Agreement and carry out all the provisions of this Agreement; (ii) it is
authorized to execute this Agreement on its behalf; (iii) the person executing
this Agreement is duly authorized to do so; and (iv) no consent, approval or
authorization of any other party is required in connection with entering into
this Agreement.

       

      SECTION
10

      Term and Termination

       

      10.1          Unless
earlier terminated, as hereinafter provided, the term of this Agreement shall
expire on a country-by-country basis at such time when no Valid Claim exists, or
if no Patent was issued in a country, on the eleventh anniversary of the First
Commercial Sale in such country, thereafter the License in such country shall
expire, provided in each case that Company may extend the term of the Agreement
on a country-by-country basis for additional period of one year each by
continuing to pay the consideration set forth in section 3. In countires where a
Patent was registered, after the expiration of Patent, Company shall have a
perpetual, worldwide, royalty-free, fully paid-up and sublicenseable License in
relation to that Patent.

       

      10.2          In
the event of a material default or failure by Company to perform any of the terms,
covenants or provisions of this Agreement, Company shall have
ninety (90) days after the giving of written notice of such default by Yissum to
correct such default, provided, however, that if the breach is not capable of
being cured within ninety (90) days of such written notice, the Agreement may not be terminated so long as Company commences
and is taking commercially reasonable actions to cure such breach as promptly as
practicable. In any event, if a curable breach has not been cured within ninety
(90) days after notice requesting cure, Yissum shall have the right, at its
option, to terminate this Agreement.

       

      10.3          Yissum
shall have the right, at its option, to terminate this Agreement in the event
that Company shall become involved in insolvency, bankruptcy, liquidation,
winding-up or receivership proceedings. Company shall immediately notify Yissum
upon commencement of any bankruptcy, insolvency, liquidation, winding-up or
receivership proceedings or the placing of an attachment on its
assets.

       

      10.4          In
the event of termination of this Agreement for any reason whatsoever, the
License shall terminate and all rights to the Licensed Technology (including
Research Results) shall revert to Yissum and Company may make no further use
thereof. Notwithstanding the aforesaid, the expiration or termination of this
Agreement shall not release Company from its obligation to carry out any
financial or other obligation which it was liable to perform prior to the
Agreement’s expiration or termination, including the payment of Royalties and
Sub-License Revenues.

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

       

      10.5          Upon
termination of this Agreement for any reason, nothing herein shall be construed
to release either Party from any obligation that matured prior to the effective
date of such termination; and Articles 1, 5, 7, 8, 9, 10, 11, 12 and 13 shall
survive any such termination.

       

      10.6          No
termination of this Agreement shall constitute a termination or a waiver of any
rights of either Party against the other Party accruing at or prior to the time
of such termination.

       

      10.7          Company
shall have the right to terminate this Agreement at any time on three (3) months
advance notice to Yissum, and upon payment of all amounts due to Yissum through
the effective date of termination.

       

      SECTION
11

      Law

       

      11.1          The
provisions of this Agreement and everything concerning the relationship between
the parties in accordance with this Agreement shall be governed by the law of
the State of Israel and, subject to Section 12 below, jurisdiction shall be
granted only to the appropriate court in Jerusalem. Any and all proceedings,
documents and other communications or correspondences between the parties shall
be in the English language.

       

      11.2          Notwithstanding
the above, Company hereby agrees that, in the event that no treaty exists
upholding the enforceability of temporary orders and/or judgments issued by
Israeli courts in the foreign jurisdiction in which Yissum may require such an
order and/or judgment to be upheld, Yissum may, at its own discretion, elect the
place of jurisdiction for the obtaining of orders and/or judgments against
Company. Company undertakes not to object to the enforcement against it of
orders and/or judgments issued by any aforesaid jurisdiction under such
circumstances.

       

      SECTION 12

      Arbitration

       

      12.1          All
differences and disputes arising between the parties in connection with this
Agreement and/or its interpretation and/or its performance and/or breach, shall
be referred for the decision of a single arbitrator, who shall be appointed by
Agreement between the parties.

       

      12.2          Should
the parties not reach agreement as to the arbitrator’s identity, the arbitrator
shall be appointed by the Chairman of the Israeli Bar Association on the
application of either of the parties.

       

      12.3          The
arbitration shall be held in Israel. The arbitrator shall not be bound by the
civil procedure regulations and laws of evidence, but shall be bound by the
substantive law of Israel and be liable to give grounds for his
decision.

       

      12.4          The
arbitrator’s decision shall be final and shall bind the parties.

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

       

      SECTION
13

      Miscellaneous

       

      13.1          This
Agreement shall be binding upon and shall inure to the benefit of Yissum and its
assigns and successors in interest, and shall be binding upon and shall inure to
the benefit of Company and its assigns and successors to all or substantially
all of its assets or business to which this Agreement relates, but shall not
otherwise be assignable or assigned by Company without prior written approval by
Yissum being first obtained, which approval shall not be unreasonably
withheld.

       

      13.2          If
any provision of this Agreement shall be declared by a court of competent
jurisdiction to be invalid, illegal or incapable of being enforced in whole or
in part, the remaining conditions and provisions or portions thereof shall
nevertheless remain in full force and effect and enforceable to the extent they
are valid, legal and enforceably, and no provision shall be deemed dependent
upon any other covenant or provision unless so expressed herein.

       

      13.3          Each
Party hereby agrees that it does not intend to violate any public policy,
statutory or common law, rule, regulation, treaty or decision of any government
agency or executive body thereof of any country or community or association of
countries; that if any word, sentence, paragraph or clause or combination
thereof of this Agreement is found, by a court or executive body with judicial
powers having jurisdiction over this Agreement or any of its Parties hereto, in
a final unappealed order to be in violation of any such provision in any country
or community or association of countries, such words, sentences, paragraphs or
clauses or combination shall be inoperative in such country or community or
association of countries, and the remainder of this Agreement shall remain
binding upon the Parties hereto.

       

      13.4          The
Parties covenant and agree that if a Party fails or neglects for any reason to
take advantage of any of the terms provided for the termination of this
Agreement or if a Party, having the right to declare this Agreement terminated,
shall fail to do so, any such failure or neglect by such Party shall not be a
waiver or be deemed or be construed to be a waiver of any cause for the
termination of this Agreement subsequently arising, or as a waiver of any of the
terms, covenants or conditions of this Agreement or of the performance thereof.
None of the terms, covenants and conditions of this Agreement may be waived by a
Party except by its written consent. A waiver by Yissum of any breach by Company
of any provision or condition of this Agreement to be performed by Company shall
not be deemed a waiver of similar or dissimilar provisions or conditions at the
same or any prior or subsequent time.

       

      13.5          This
Agreement contains the entire agreement and understanding of the Parties with
respect to the subject matter hereof, supersedes any prior agreements and
understandings with respect thereto and cannot be modified, amended or waived,
in whole or in part, except in writing signed by the Parties.

       

      13.6          Each
Party shall bear its own legal expenses involved in the making of this
Agreement.

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

       

      13.7          The
headings to the sections in this agreement are for the sake of convenience only
and shall not serve in the Agreement’s interpretation.

       

      13.8          Company
shall disclose to Yissum any existing agreement and/or arrangement or
relationship of any kind between it and employees of Yissum and/or the Hebrew
University of Jerusalem with respect to the Licensed Technology and in
connection therewith and shall not enter into any agreement or arrangement with
any employees of Yissum and/or the Hebrew University of Jerusalem, as aforesaid,
without the prior written consent of Yissum.

       

      13.9          The
appendixes annexed hereto constitute an integral part hereof and shall be read
jointly with its terms and provisions.

       

      13.10        The
recitals hereto constitute an integral part hereof. In this Agreement, unless
otherwise required or indicated by the context, the singular shall include the
plural and vice-versa, and the masculine gender shall include all other
genders.

       

      SECTION
14

      Notices

       

      All
notices and communications pursuant to this Agreement shall be made in writing
and sent by registered mail to or served in person at the following
addresses:

       

      (i)         If
to Yissum:

       

      YISSUM
RESEARCH DEVELOPMENT COMPANY

      OF THE
HEBREW UNIVERSITY OF
JERUSALEM

      Hi-Tech
Park, Edmond J. Safra
Campus

      Givat
Ram, P.O.Box 39135, Jerusalem 91390, Israel

       

      (ii)         If
to Company:

       

      BIOCANCELL
PHARMACEUTICALS INC.

      2711
Centerville Road, Suite 400

      Wilmington,
New Castle County, Delaware, 19808

       

      and

       

      BIOCANCELL
PHARMACEUTICALS LTD.

      Hi-Tech
Park, Edmond J. Safra Campus

      Givat
Ram, P.O.Box 39135, Jerusalem, 91390, Israel

       

      or such
other address furnished in writing by one Party to the other. Any notice sent as
aforesaid shall be deemed to have been received five (5) days after being posted
by registered mail, or one (1) day following the date of personal
service.

      
        
           

        

        
           

          
            

          

        

        
           

        

      

      

      [REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK)

      
        
           

        

        
           

          
            

          

        

        
           

        

      

     

    IN
WITNESS WHEREOF, the Parties hereto have executed and delivered this Agreement
in multiple originals by their duly authorized officers and representatives on
the respective dates shown below, but effective as of the Effective
Date.

     

    YISSUM
RESEARCH DEVELOPMENT COMPANY

    OF
THE HEBREW UNIVERSITY OF JERUSALEM

     

    
      
        
          
            
              
                
                  
                    
                      
                        
                          
                            
                              
                                	
                                        By:

                                      	
                                        /s/
      Herve Bercovier

                                      	 
      	
                                        By:

                                      	
                                        /s/
      Reuven Ron

                                      
	 	 	 	 	 
	
                                        Name:

                                      	
                                        Prof.
      Herve Bercovier

                                      	 
      	
                                        Name:

                                      	
                                        Reuven
      Ron

                                      
	 	 	 	 	 
	
                                        Title:

                                      	
                                        Director

                                      	 
      	
                                        Title:

                                      	
                                        VP
      Marketing

                                      
	 	 	 	 	 
	
                                        Date:

                                      	
                                        November
      14, 2005

                                      	 
      	
                                        Date:

                                      	
                                        November
      14,
2005

                                      

                              

                            

                          

                        

                      

                    

                  

                

              

            

          

        

      

    

     

     

    BIOCANCELL
PHARMACEUTICALS INC.

    

    
      
        
          
            
              
                
                  
                    
                      
                        
                          
                            
                              
                                	
                                        By:

                                      	
                                        /s/
      Avi Barak

                                      	 
      	
                                        By:

                                      	
                                        /s/
      Uri Danon

                                      
	 	 	 	 	 
	
                                        Name:

                                      	
                                        Avi
      Barak

                                      	 
      	
                                        Name:

                                      	
                                        Uri
      Danon

                                      
	 	 	 	 	 
	
                                        Title:

                                      	
                                        Chairman

                                      	 
      	
                                        Title:

                                      	
                                        President

                                      
	 	 	 	 	 
	
                                        Date:

                                      	
                                        Nov
      14, 2005

                                      	 
      	
                                        Date:

                                      	
                                        November
      14,
2005

                                      

                              

                            

                          

                        

                      

                    

                  

                

              

            

          

        

      

    

     

     

    BIOCANCELL
PHARMACEUTICALS LTD.

    

    
      
        
          
            
              
                
                  
                    
                      
                        
                          
                            
                              	
                                      By:

                                    	
                                      /s/
      Avi Barak

                                    	 
      	
                                      By:

                                    	
                                      /s/
      Uri Danon

                                    
	 	 	 	 	 
	
                                      Name:

                                    	
                                      Avi
      Barak

                                    	 
      	
                                      Name:

                                    	
                                      Uri
      Danon

                                    
	 	 	 	 	 
	
                                      Title:

                                    	
                                      Chairman

                                    	 
      	
                                      Title:

                                    	
                                      President

                                    
	 	 	 	 	 
	
                                      Date:

                                    	
                                      Nov
      14, 2005

                                    	 
      	
                                      Date:

                                    	
                                      November
      14,
2005

                                    

                            

                          

                        

                      

                    

                  

                

              

            

          

        

      

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

       

      APPENDIX
1 - PATENTS

    

     

    
      
        	
                2148 

              	
                DIAGNOSTIC
      ASSAY FOR MALIGNANCIES USING H-19 GENE,
KIT

              

      

      Inventors:
ARIEL ILANA, HOCHBERG ABRAHAM

    

     

    
      
        
          
            
              
                
                  
                    
                      
                        
                          
                            
                              
                                	
                                        File

                                      	 	
                                        Country

                                      	 
      	
                                        Status

                                      	 	
                                        Appl

                                        Date

                                      	 
      	
                                        Appl

                                        No

                                      	 
      	
                                        Reg

                                        Date

                                      	 
      	
                                        Reg

                                        No

                                      	 
      	
                                        Pub

                                        Date

                                      	 
      	
                                        Pub

                                        No

                                      
	
                                        2148-00

                                      	 
      	
                                        Israel

                                      	 
      	
                                        Granted

                                      	 	
                                        7/Mar/94

                                      	 
      	
                                        108879

                                      	 
      	
                                        3/Dec/00

                                      	 
      	
                                        108879

                                      	 
      	 
      	 
      	 
      
	
                                        2148-01

                                      	 
      	
                                        PCT

                                      	 
      	
                                        Published

                                      	 	
                                        6/Mar/95

                                      	 
      	
                                        PCT/EP95/00823

                                      	 
      	 
      	 
      	 
      	 
      	
                                        14/Sep/95

                                      	 
      	
                                        WO95/24503

                                      
	
                                        2148-03

                                      	 
      	
                                        US

                                      	 
      	
                                        Granted

                                      	 	
                                        6/Sep/96

                                      	 
      	
                                        08/704,786

                                      	 
      	
                                        21/Sep/99

                                      	 
      	
                                        5,955,273

                                      	 
      	 
      	 
      	 
      
	
                                        2148-04

                                      	
                                          

                                      	
                                        Europe

                                      	
                                          

                                      	
                                        Granted

                                      	
                                         

                                      	
                                        6/Mar/95

                                      	
                                          

                                      	
                                        95927570.2

                                      	
                                          

                                      	
                                        29/May/02

                                      	
                                          

                                      	
                                        0759092

                                      	
                                          

                                      	 
      	
                                          

                                      	 
      

                              

                            

                          

                        

                      

                    

                  

                

              

            

          

        

      

    

     

    
      
        	
                2324 

              	
                METHODS
      AND COMPOSITIONS FOR INDUCING TUMOR-SPECIFIC
  CYTOTOXICITY

              

      

    

    Inventors:
AYESH SUHAIL, HOCHBERG ABRAHAM

     

    
      
        
          
            
              
                
                  
                    
                      
                        
                          
                            
                              
                                
                                  	
                                          File

                                        	 
      	
                                          Country

                                        	 
      	
                                          Status

                                        	 
      	
                                          Appl

                                          Date

                                        	 
      	
                                          Appl

                                          No

                                        	 
      	
                                          Reg

                                          Date

                                        	 
      	
                                          Reg

                                          No

                                        	 
      	
                                          Pub

                                          Date

                                        	 
      	
                                          Pub

                                          No

                                        
	
                                          2324-00

                                        	 
      	
                                          US

                                        	 
      	
                                          Abandoned

                                        	 
      	
                                          3/Oct/97

                                        	 
      	
                                          08/943,608

                                        	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      
	
                                          2324-01

                                        	 
      	
                                          PCT

                                        	 
      	
                                          Published

                                        	 
      	
                                          4/Oct/98

                                        	 
      	
                                          PCT/IL98/00486

                                        	 
      	 
      	 
      	 
      	 
      	
                                          15/Apr/99

                                        	 
      	
                                          WO
      99/18195

                                        
	
                                          2324-02

                                        	 
      	
                                          PCT

                                        	 
      	
                                          Published

                                        	 
      	
                                          22/Oct/02

                                        	 
      	
                                          PCT/IL02/00843

                                        	 
      	 
      	 
      	 
      	 
      	
                                          1/May/03

                                        	 
      	
                                          WO
      03/035883

                                        
	
                                          2324-03

                                        	 
      	
                                          Brazil

                                        	 
      	
                                          Filed

                                        	 
      	
                                          4/Oct/98

                                        	 
      	
                                          PI9812717-9

                                        	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      
	
                                          2324-03

                                        	 
      	
                                          US

                                        	 
      	
                                          Granted

                                        	 
      	
                                          l/Oct/98

                                        	 
      	
                                          09/165,240

                                        	 
      	
                                          11/Jul/00

                                        	 
      	
                                          6,087,164

                                        	 
      	 
      	 
      	 
      
	
                                          2324-04

                                        	 
      	
                                          China

                                        	 
      	
                                          Exam

                                        	 
      	
                                          4/Oct/98

                                        	 
      	
                                          98811833.5

                                        	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      
	
                                          2324-05

                                        	 
      	
                                          Europe

                                        	 
      	
                                          Published

                                        	 
      	
                                          4/Oct/98

                                        	 
      	
                                          98947759.1

                                        	 
      	 
      	 
      	 
      	 
      	 
      	 
      	
                                          1019499

                                        
	
                                          2324-06

                                        	 
      	
                                          Hungary

                                        	 
      	
                                          Filed

                                        	 
      	
                                          4/Oct/98

                                        	 
      	
                                          P0003745

                                        	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      
	
                                          2324-07

                                        	 
      	
                                          Israel

                                        	 
      	
                                          Filed

                                        	 
      	
                                          4/Oct/98

                                        	 
      	
                                          135430

                                        	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      
	
                                          2324-08

                                        	 
      	
                                          Korea

                                        	 
      	
                                          Exam

                                        	 
      	
                                          4/Oct/98

                                        	 
      	
                                          2000-7003609

                                        	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      
	 
      	 
      	
                                          Mexico

                                        	 
      	
                                          Filed

                                        	 
      	
                                          4/Oct/98

                                        	 
      	
                                          2000003251

                                        	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      
	
                                          2324-09

                                        	 
      	
                                          Mexico

                                        	 
      	
                                          Filed

                                        	 
      	
                                          4/Oct/98

                                        	 
      	
                                          2000-003843

                                        	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      
	
                                          2324-10

                                        	 
      	
                                          New
      Zealand

                                        	 
      	
                                          Filed

                                        	 
      	
                                          4/Oct/98

                                        	 
      	
                                          503843

                                        	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      
	
                                          2324-11

                                        	 
      	
                                          Norway

                                        	 
      	
                                          Filed

                                        	 
      	
                                          4/Oct/98

                                        	 
      	
                                          20001684

                                        	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      
	
                                          2324-12

                                        	 
      	
                                          Poland

                                        	 
      	
                                          Filed

                                        	 
      	
                                          4/Oct/98

                                        	 
      	
                                          P339949

                                        	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      
	
                                          2324-13

                                        	 
      	
                                          Russia

                                        	 
      	
                                          Granted

                                        	 
      	
                                          4/Oct/98

                                        	 
      	
                                          2000111553

                                        	 
      	
                                          22/Oct/03

                                        	 
      	
                                          2214280

                                        	 
      	 
      	 
      	 
      
	
                                          2324-14

                                        	 
      	
                                          US

                                        	 
      	
                                          Granted

                                        	 
      	
                                          10/May/00

                                        	 
      	
                                          09/568,059

                                        	 
      	
                                          23/Oct/01

                                        	 
      	
                                          6,306,833

                                        	 
      	 
      	 
      	 
      
	
                                          2324-15

                                        	 
      	
                                          US

                                        	 
      	
                                          Exam

                                        	 
      	
                                          22/Oct/01

                                        	 
      	
                                          10/012,131

                                        	 
      	
                                           
      

                                        	 
      	 
      	 
      	 
      	 
      	
                                          US-2004-0082529

                                        
	
                                          2324-16

                                        	 
      	
                                          Australia

                                        	 
      	
                                          Granted

                                        	 
      	
                                          4/Oct/98

                                        	 
      	
                                          94571/98

                                        	 
      	
                                          19/Dec/02

                                        	 
      	
                                          755774

                                        	 
      	 
      	 
      	 
      
	
                                          2324-17

                                        	 
      	
                                          Japan

                                        	 
      	
                                          Exam

                                        	 
      	
                                          4/Oct/98

                                        	 
      	
                                          2000-514993

                                        	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      
	
                                          2324-18

                                        	 
      	
                                          Canada

                                        	 
      	
                                          Exam

                                        	 
      	
                                          4/Oct/98

                                        	 
      	
                                          2,308,124

                                        	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      
	
                                          2324-19

                                        	 
      	
                                          Singapore

                                        	 
      	
                                          Granted

                                        	 
      	
                                          4/Oct/98

                                        	 
      	
                                          200001824-2

                                        	 
      	
                                          4/Jun/02

                                        	 
      	
                                          72207

                                        	 
      	 
      	 
      	 
      
	
                                          2324-20

                                        	 
      	
                                          Czech
      Republic

                                        	 
      	
                                          Exam

                                        	 
      	
                                          4/Oct/98

                                        	 
      	
                                          PV2000-1201

                                        	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      
	
                                          2324-21

                                        	 
      	
                                          Europe

                                        	 
      	
                                          Published

                                        	 
      	
                                          22/Oct/02

                                        	 
      	
                                          02779859.4

                                        	 
      	 
      	 
      	 
      	 
      	 
      	 
      	
                                          1438412

                                        
	
                                          2324-22

                                        	 
      	
                                          China

                                        	 
      	
                                          Filed

                                        	 
      	
                                          22/Oct/02

                                        	 
      	
                                          02825940.8

                                        	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      
	
                                          2324-23

                                        	 
      	
                                          Japan

                                        	 
      	
                                          Filed

                                        	 
      	
                                          22/Oct/02

                                        	 
      	
                                          2003-538383

                                        	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      
	
                                          2324-24

                                        	 
      	
                                          Israel

                                        	 
      	
                                          Filed

                                        	 
      	
                                          22/Oct/02

                                        	 
      	
                                          161553

                                        	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      
	
                                          2324-25

                                        	 
      	
                                          Canada

                                        	 
      	
                                          Filed

                                        	 
      	
                                          22/Oct/02

                                        	 
      	
                                          2,464,394

                                        	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      
	
                                          2324-26

                                        	 
      	
                                          Australia

                                        	 
      	
                                          Filed

                                        	 
      	
                                          22/Oct/02

                                        	 
      	
                                          2002343189

                                        	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      
	
                                          2324-27

                                        	 
      	
                                          Mexico

                                        	 
      	
                                          Filed

                                        	 
      	
                                          22/Oct/02

                                        	 
      	
                                          PAa2004/003732

                                        	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      
	
                                          2324-28

                                        	
                                            

                                        	
                                          Czech
      Republic

                                        	
                                            

                                        	
                                          Filed

                                        	
                                            

                                        	
                                          18/Jun/04

                                        	
                                            

                                        	
                                          PV
      2004-741

                                        	
                                            

                                        	 
      	
                                            

                                        	 
      	
                                            

                                        	 
      	
                                            

                                        	 
      

                                

                              

                            

                          

                        

                      

                    

                  

                

              

            

          

        

      

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      	
              2617 

            	
              TRACKING
      GENE EXPRESSION

            

    

    
      	
               

            	
              Inventors:
      HOCHBERG ABRAHAM, HONIGMAN ALIK, ZEIRA EVELYN, AXELROD JONATHAN, GOMORI
      MOSHE, TAVOR EINAT, GILADI HILA, GALUN
EITAN

            

    

     

    
      
        
          
            
              
                
                  
                    
                      
                        
                          
                            
                              	
                                      File

                                    	 
      	
                                      Country

                                    	 
      	
                                      Status

                                    	 
      	
                                      Appl

                                      Date

                                    	 
      	
                                      Appl

                                      No

                                    	 
      	
                                      Reg

                                      Date

                                    	 
      	
                                      Reg

                                      No

                                    	 
      	
                                      Pub

                                      Date

                                    	 
      	
                                      Pub

                                      No

                                    
	
                                      2617-00

                                    	 
      	
                                      US

                                    	 
      	
                                      Provisional

                                    	 
      	
                                      31/Jan/00

                                    	 
      	
                                      60/179,139

                                    	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      
	
                                      2617-01

                                    	 
      	
                                      US

                                    	 
      	
                                      Provisional

                                    	 
      	
                                      27/Dec/00

                                    	
                                        

                                    	
                                      60/758,038

                                    	
                                        

                                    	 
      	
                                        

                                    	 
      	
                                        

                                    	 
      	
                                        

                                    	 
      

                            

                          

                        

                      

                    

                  

                

              

            

          

        

      

      

      
        	
                2807

              	
                METHOD
      FOR DETECTION OF MICRO-METASTASIS

              

      

      
        	
                 
      

              	
                Inventors:
      HOCHBERG ABRAHAM

              

      

      

      
        
          
            
              
                
                  
                    
                      
                        
                          
                            
                              	
                                      File

                                    	 
      	
                                      Country

                                    	 
      	
                                      Status

                                    	 
      	
                                      Appl

                                      Date

                                    	 
      	
                                      Appl

                                      No

                                    	 
      	
                                      Reg

                                      Date

                                    	 
      	
                                      Reg

                                      No

                                    	 
      	
                                      Pub

                                      Date

                                    	 
      	
                                      Pub

                                      No

                                    
	
                                      2807-00

                                    	 
      	
                                      US

                                    	 
      	
                                      Exhausted

                                    	 
      	
                                      12/Sep/02

                                    	 
      	
                                      60/409,975

                                    	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      
	
                                      2807-01

                                    	
                                        

                                    	
                                      PCT

                                    	
                                        

                                    	
                                      Published

                                    	 
      	
                                      12/Sep/03

                                    	
                                        

                                    	
                                      PCT/US03/28807

                                    	
                                        

                                    	 
      	
                                        

                                    	 
      	
                                        

                                    	 
      	
                                        

                                    	
                                      WO
      2004/024957

                                    

                            

                          

                        

                      

                    

                  

                

              

            

          

        

      

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

       

      
        	
                2808

              	
                METHOD
      FOR REGULATING EXPRESSION GENES

                Inventor: HOCHBERG ABRAHAM, AYESH SUHAIL, PORADOSU
      ENRIQUE

              

      

       

      
        
          
            
              
                
                  
                    
                      
                        
                          
                            
                              	
                                      File

                                    	 
      	
                                      Country

                                    	 
      	
                                      Status

                                    	 
      	
                                      Appl

                                      Date

                                    	 
      	
                                      Appl

                                      No

                                    	 
      	
                                      Reg

                                      Date

                                    	 
      	
                                      Reg

                                      No

                                    	 
      	
                                      Pub

                                      Date

                                    	 
      	
                                      Pub

                                      No

                                    
	
                                      2808-00

                                    	 
      	
                                      US

                                    	 
      	
                                      Provisional

                                    	 
      	
                                       
      3/Oct/02

                                    	 
      	
                                      60/415,528

                                    	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      
	
                                      2808-01

                                    	 
      	
                                      PCT

                                    	 
      	
                                      Published

                                    	 
      	
                                      3/Oct/03

                                    	 
      	
                                      PCT/US2003/031306

                                    	 
      	 
      	 
      	 
      	 
      	 
      	
                                        

                                    	
                                      WO
      2004/031359

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00150-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00150-of-00352.parquet"}]]